Jacinth W. Cheu

Hong Kong Science Park
Hong Kong, HCW, Hong Kong Special Administrative Region

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

The Diverse Roles of Lipid Metabolism Reprogramming in Shaping the Tumor Immune Microenvironment.

The Diverse Roles of Lipid Metabolism Reprogramming in Shaping the Tumor Immune Microenvironment.

Journal: Cancer research

Published: June 17, 2025

BCAT1-dependent HIF-1α stabilization is a targetable metabolic vulnerability in hepatocellular carcinoma.

BCAT1-dependent HIF-1α stabilization is a targetable metabolic vulnerability in hepatocellular carcinoma.

Journal: Cell reports. Medicine

Published: September 06, 2024

Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification.

Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification.

Journal: Journal of hepatology

Published: August 16, 2024

The immune microenvironment of steatotic hepatocellular carcinoma: Current findings and future prospects.

The immune microenvironment of steatotic hepatocellular carcinoma: Current findings and future prospects.

Journal: Hepatology communications

Published: July 09, 2024

Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development.

Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development.

Journal: Science advances

Published: May 05, 2023

Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma.

Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: December 14, 2022

CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.

CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 01, 2022

Ferroptosis Suppressor Protein 1 Inhibition Promotes Tumor Ferroptosis and Anti-tumor Immune Responses in Liver Cancer.

Ferroptosis Suppressor Protein 1 Inhibition Promotes Tumor Ferroptosis and Anti-tumor Immune Responses in Liver Cancer.

Journal: Cellular and molecular gastroenterology and hepatology

Published: February 04, 2022

Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.

Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.

Journal: Hepatology (Baltimore, Md.)

Published: August 30, 2021

Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.

Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.

Journal: Journal of hepatology

Published: April 11, 2021

Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors.

Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors.

Journal: Hepatology (Baltimore, Md.)

Published: February 01, 2021

Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma.

Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma.

Journal: Nature communications

Published: August 15, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026